Semaglutide works by suppressing appetite and reducing hunger
However, there may be exceptional circumstances where dose escalation is delayed, such as: Significant gastrointestinal side effects that have not resolved after one month Concurrent acute illness or hospitalisation Patient preference to extend the titration period under medical supervision Concerns about tolerability in frail or elderly patients Healthcare professionals should review patients after starting Rybelsus to assess tolerability, reinforce dosing instructions, and plan dose escalation
GLP-1 is a hormone secreted by the small intestine that promotes insulin secretion, inhibits glucagon release, and slows gastrointestinal emptying
Semaglutide, a GLP-1 receptor agonist, plays a notable role after bariatric surgery by assisting in maintaining weight loss and promoting healthier eating habits
Quick Answer: Weakness on semaglutide typically results from reduced caloric intake due to appetite suppression, gastrointestinal side effects causing dehydration and electrolyte imbalances, and rapid weight loss rather than direct medication toxicity